Die Fundamentaldaten des Unternehmens sind relativ schwach. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Halten bewertet. Trotz einer durchschnittlichen Börsenleistung zeigt das Unternehmen starke technische Aspekte. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Zugehörige Informationen
Branchenrang
193 / 506
Gesamtwertung
313 / 4720
Branche
Biotechnologie & Medizinische Forschung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
1
Analysten
Halten
Aktuelles Rating
12.500
Kursziel
+1517.29%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.